Elliot Ehrich, M.D., who capped an 18-year career at Alkermes in January, has joined Expansion Therapeutics as its chief medical officer.
Deerfield Management committed up to $80 million to fund a new center at the Dana-Farber Cancer Institute set on exploring protein degradation.
Mesoblast shares dive after its stem cell therapy fails to wean heart failure patients off left ventricular assist devices in a phase 2 trial.
The financing, which comes 15 months after Roivant raised $1.1 billion, is tied to a $7 billion valuation for the fast-growing biotech.
NextCure will use the series B funds to advance Siglec-15-targeting antibody NC318 and another asset through early-phase clinical development.
Kymera Therapeutics raised $65 million in series B funding that will support the clinical development of its lead protein degradation program.
Ribometrix raised $30 million to fund its platform that fits small molecules into the 3D folds and pockets of RNA structures to modulate their activity.
Two years after Nestlé Health Science poured $145 million into Aimmune, the company is boosting its total investment in the biotech to $273 million.
Quantum Genomics’ blood pressure drug firibastat met its endpoints in a phase 2b study, paving the way for a wider trial in resistant hypertension.
Combining a RIP1 inhibitor with Merck's hit checkpoint inhibitor Keytruda holds promise in treating pancreatic cancer, GSK says.